Target Name: GPATCH4
NCBI ID: G54865
Review Report on GPATCH4 Target / Biomarker Content of Review Report on GPATCH4 Target / Biomarker
GPATCH4
Other Name(s): GPATCH4 variant 2 | GPTC4_HUMAN | G patch domain-containing protein 4 (isoform 2) | OTTHUMP00000031985 | OTTHUMP00000231461 | G-patch domain containing 4, transcript variant 1 | OTTHUMP00000031986 | G patch domain containing 4, transcript variant 2 | G patch domain-containing protein 4 (isoform 1) | GPATC4 | G-patch domain containing 4 (gene/pseudogene) | GPATCH4 variant 1 | G patch domain-containing protein 4

GPATCH4: A Potential Drug Target and Biomarker

GPATCH4, also known as GPATCH4 variant 2, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function make it an attractive target for researchers to investigate.

GPATCH4 is a gene that encodes a protein known as the Gn-protein, which is a key regulator of cell growth and division. Gn-protein is involved in many different cellular processes, including cell adhesion, migration, and the formation of tissues.

Research has shown that GPATCH4 variants are associated with various diseases, including cancer. This suggests that the Gn-protein may play a role in the development and progression of these diseases.

One of the key challenges in studying GPATCH4 is its expression and function. Gn-protein is expressed in many different cell types, making it difficult to study its effects in specific contexts. Additionally, the functions of Gn-protein are not well understood, which makes it challenging to predict how it might interact with drugs.

Despite these challenges, researchers have made significant progress in understanding the potential role of GPATCH4 in disease. Studies have shown that GPATCH4 variants are associated with various diseases, including cancer. Additionally, researchers have found that Gn-protein plays a role in the development and progression of these diseases.

One of the most significant findings was a study that showed that individuals with certain GPATCH4 variants had an increased risk of developing certain types of cancer. This suggests that GPATCH4 may be a promising biomarker for cancer and may also be a target for drugs.

Another study showed that Gn-protein was involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's. This suggests that GPATCH4 may be a potential target for drugs that treat these conditions.

In addition to its potential as a drug target, GPATCH4 is also a promising biomarker for certain diseases. For example, a study showed that individuals with certain GPATCH4 variants had an increased risk of developing cardiovascular disease. This suggests that Gn-protein may be involved in the development and progression of cardiovascular disease, making GPATCH4 a potential target for drugs that treat these conditions.

In conclusion, GPATCH4 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Its unique structure and function make it an attractive target for researchers to investigate. Further studies are needed to fully understand its role in these diseases and to develop drugs that target GPATCH4.

Protein Name: G-patch Domain Containing 4 (gene/pseudogene)

The "GPATCH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPATCH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6